NewLink Genetics

NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2, 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.
Ames, US
210 (est)+126%
NewLink Genetics was founded in 1999 and is headquartered in Ames, US

NewLink Genetics Locations

Ames, US
Austin, US
Devens, US

NewLink Genetics Metrics

NewLink Genetics Summary

Market capitalization

$324 M

Closing share price

NewLink Genetics's current market capitalization is $324 M.

NewLink Genetics Financials

NewLink Genetics's revenue is $68.5 M in FY, 2015 which is 60.31% decrease from the previous period.
FY, 2013FY, 2014FY, 2015


$173 M$68.5 M

Operating income

$-139 M$118 M$-33.6 M

Operating expense total

$147 M$55 M$102 M

Net Income

$-137 M$103 M$-40.4 M

Operating cash flow

$61.3 M$129 M$5.22 M

    NewLink Genetics Market Value History

    NewLink Genetics News

    NewLink Genetics Company Life

    You may also be interested in